1. Home
  2. VS vs NRSN Comparison

VS vs NRSN Comparison

Compare VS & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Versus Systems Inc.

VS

Versus Systems Inc.

N/A

Current Price

$0.74

Market Cap

7.9M

Sector

Technology

ML Signal

N/A

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

N/A

Current Price

$1.78

Market Cap

7.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VS
NRSN
Founded
2013
2017
Country
United States
Israel
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
7.6M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
VS
NRSN
Price
$0.74
$1.78
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $91.75
AVG Volume (30 Days)
12.3K
★ 42.0K
Earning Date
11-24-2026
09-25-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 75.97
N/A
EPS
N/A
★ N/A
Revenue
★ $2,183,415.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3711.30
N/A
52 Week Low
$0.70
$0.25
52 Week High
$1.86
$7.50

Technical Indicators

Market Signals
Indicator
VS
NRSN
Relative Strength Index (RSI) 31.82 38.89
Support Level N/A $0.59
Resistance Level $1.18 $7.50
Average True Range (ATR) 0.08 0.31
MACD -0.01 0.05
Stochastic Oscillator 15.14 45.34

Price Performance

Historical Comparison
VS
NRSN

About VS Versus Systems Inc.

Versus Systems Inc operates within the technology sector, focusing on engagement-enhancing solutions through its proprietary prizing and promotions platform. This technology enables developers and content creators across streaming, live events, broadcast, gaming, and other media to integrate real-world prizes into their experiences, fostering greater consumer interaction and providing a compelling opportunity for brand partners and advertisers. The company operates in Canada and the USA.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: